financetom
Business
financetom
/
Business
/
Intel director Lip-Bu Tan is leaving chipmaker's board, Bloomberg News reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Intel director Lip-Bu Tan is leaving chipmaker's board, Bloomberg News reports
Aug 23, 2024 12:37 AM

Aug 22 (Reuters) - Intel's ( INTC ) director Lip-Bu Tan,

a semiconductor industry veteran brought in 2022 to help with

the chipmaker's comeback effort, is stepping down from its

board, Bloomberg News reported on Thursday, citing people

familiar with the situation.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Natera Q2 revenue rises 32.2%, raises 2025 outlook
Natera Q2 revenue rises 32.2%, raises 2025 outlook
Aug 7, 2025
Overview * Natera Q2 2025 revenue rises 32.2% yr/yr to $546.6 mln * Company raises 2025 annual revenue outlook by $80 mln at midpoint * Net loss widens to $100.9 mln in the qtr Outlook * Natera ( NTRA ) raises 2025 revenue outlook to $2.02 bln - $2.10 bln * Company expects 2025 gross margin of 61% to 64%...
Biopharma firm Verastem Oncology Q2 net loss widens
Biopharma firm Verastem Oncology Q2 net loss widens
Aug 7, 2025
Overview * Verastem Q2 2025 net product revenue reaches $2.1 mln post AVMAPKI FAKZYNJA launch * Net loss for Q2 2025 widens to $25.9 mln, driven by increased expenses * Company ends Q2 2025 with $164.3 mln cash, runway into H2 2026 Result Drivers * AVMAPKI FAKZYNJA LAUNCH - Achieved $2.1 mln in net product revenue in first six weeks...
Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk (UPDATED)
Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk (UPDATED)
Aug 7, 2025
Eli Lilly and Co ( LLY ). stock plunged on Thursday after the company released topline data from the Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist. The trial included over 3,000 obese patients with a weight-related medical problem and without diabetes. At 72 weeks, all three doses of orforglipron met the primary endpoint...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved